TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03455673

Intervention type: DIAGNOSTIC_TEST
Intervention: ATE score
Description: The Atrial Thrombus Exclusion (ATE) combine thromboembolic risk factors (hypertension, cardiac insufficiency, history of stoke) and d-dimer level for the prediction of intra-atrial thrombus :~Hypertension = 1 Heart failure = 1 History of stroke = 1 High plasma d-dimer level (\> 270 ng/ml) = 1
Study: NCT02365623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207 (bedaquiline)
Description: TMC207 (bedaquiline): Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4\*100 mg tablets once daily 2 weeks (14 days) followed by 200 mg (2 tablets) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Regimen (BR)
Description: Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide \[PZA\], ethambutol \[EB, EMB\], streptomycin \[SM\], kanamycin \[KM, KAN\], enviomycin \[EVM\], ethionamide \[TH\], cycloserine \[CS\], para-aminosalicylic acid \[PAS\], amikacin \[AMK\], levofloxacin \[LVFX\] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
Study: NCT03283202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avadomide (CC-122)
Description: Avadomide (CC-122) by mouth at the assigned dose in Ph 1 starting on Day 1 for 5 consecutive days per week, followed by 2 days without avadomide (CC-122) administration (5/7) for the first two weeks of a 21-day treatment cycle. If the highest proposed dose level to be explored in Phase 1 is applied, the dosing regimen will be 5/7 days for all 3 weeks of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituxan 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 750mg/m2 by IV infusion
Description: Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) on Day 1 by IV bolus on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
Study: NCT03411395

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5AA+CrPic Water
Description: Dietary supplement drink with carbonation, aroma, amino acids and chromium picolinate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5AA+CrPic Water
Description: Dietary supplement drink with carbonation, aroma, amino acids and chromium picolinate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5AA+CrPic Water
Description: Dietary supplement drink with carbonation, aroma, amino acids and chromium picolinate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Placebo water with carbonation and aroma
Study: NCT03346330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-750
Description: TRK-750 capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT00282126

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium citrate
Description: kcitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium citrate
Description: kcitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Potassium citrate
Description: kcitrate
Study: NCT00008385

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selenium
Description: Given orally
Study: NCT03561233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20mg
Description: omeprazole 20 mg twice daily 30 minutes before meal for 4 weeks
Study: NCT03244059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab is an anti-BLyS (B-lymphocyte stimulating factor) agent administered by infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identically appearing placebo infusion.
Study: NCT00582556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zometa
Description: GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zometa
Description: GnRH analogue 3-mo depot - q3 months for 1 yr andZometa 4 mg IV over 15 min x 1, given at mo 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zometa
Description: GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
Study: NCT02519114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Bone Marrow stem cell transplantation
Description: KIR-mismatched haploidentical Bone Marrow stem cell transplantation
Study: NCT04513483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure
Description: CPAP treatment at night. Treat AF as cardiologist's discretion.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Observation. Treat AF as cardiologist's discretion.
Study: NCT02590029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suggestion
Description: The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
Study: NCT03478618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer
Description: Patients will be divided into 2 groups according to the amount of fluids received during caesarian section under spinal anesthesia.~Group (R) 30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative. Group (L) 30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative. blood loss will be replaced if more than 500 ml in ratio 3 ml crystalloid : 1ml blood in both groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer
Description: Patients will be divided into 2 groups according to the amount of fluids received during caesarian section under spinal anesthesia.~Group (R) 30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative. Group (L) 30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative. blood loss will be replaced if more than 500 ml in ratio 3 ml crystalloid : 1ml blood in both groups
Study: NCT02235506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural infusion
Description: Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femoral sciatic
Description: After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: epidural infusion
Description: Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
Study: NCT04441970

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head rotation position
Description: The cuff pressure will be recorded at the head rotation position.
Study: NCT04155281

Intervention type: OTHER
Intervention: urine analysis
Description: New Psychoactive Substances research in urine at admission in unit care
Study: NCT01536405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMRV (AMP)
Description: Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMRV (2006 process)
Description: Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
Study: NCT01094067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-050089
Description: 5 mg/h intravenously, Tezosentan
Study: NCT03777462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant gemcitabine plus nab-paclitaxel
Description: Neoadjuvant gemcitabine plus nab-paclitaxel is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. Surgical resection will be performed after neoadjuvant chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT
Description: Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
Study: NCT01094067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-050089
Description: 5 mg/h intravenously, Tezosentan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT04165239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH176
Description: Oral administration of 50 mg KH176 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH176
Description: Oral administration of 100 mg KH176 twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of matching placebo twice daily
Study: NCT03777462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant S-1 plus nab-paclitaxel with SBRT
Description: Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
Study: NCT01484288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barostim Neo System
Description: Baroreflex Activation Therapy using the Barostim Neo System
Study: NCT01265264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulodesine
Description: Oral dose administered daily for 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulodesine
Description: Oral dose administered daily for 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulodesine
Description: Oral dose administered daily for 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulodesine
Description: Oral dose administered daily for 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulodesine
Description: Oral dose administered daily for 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose administered daily for 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose administered daily for 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose administered daily for 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose administered daily for 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose administered daily for 84 days.
Study: NCT03596749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer Carbonate
Description: Sevelamer carbonate 1600mg (p.o. b.i.d) with meals
Study: NCT02154828

Intervention type: BEHAVIORAL
Intervention: Integrative practices
Study: NCT00668993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EFT - the Emotional Freedom technique
Description: EFT combines cognitive strategies with somatic procedures adapted from acupuncture and related systems for altering the cognitive, behavioural, and neurochemical foundations of psychological problems. It is often referred to as psychological acupuncture. Few adequately controlled studies have been conducted on EFT however acupuncture has been quite extensively studied, with hundreds of research reports published
Study: NCT03345966

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bmi-1 antibody
Description: B-lymphoma Moloney murine leukemia virus insertion region-1

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bmi-1 antibody
Description: B-lymphoma Moloney murine leukemia virus insertion region-1
Study: NCT03763513

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: Extracorporeal Shock Wave Therapy=ESWT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT
Description: Extracorporeal Shock Wave Therapy=ESWT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping Application
Description: Kinesiotaping=KT (CT)
Study: NCT00771589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Knee Prosthesis
Description: Motorized External Knee Prosthesis for above knee amputees.
Study: NCT02235506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: femoral sciatic
Description: After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
Study: NCT01693445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OIS (Oxaliplatin, Irinotecan, S-1)
Description: Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~1. Oxaliplatin 85 mg/m²IV on day 1~2. Irinotecan 120 mg/m² IV on day 1~3. S-1 60 mg/m2/day PO on day 1-7~Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level.
Study: NCT04781075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Scale
Description: Maximum Daily Pain Scale will be recorded daily until discharge (typically under 7 days)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Scale
Description: Maximum Daily Pain Scale will be recorded daily until discharge (typically under 7 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Injectable Product
Description: Given at the beginning of the surgery for post-operative pain management

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Given at the beginning of the surgery for post-operative pain management
Study: NCT00700856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: add-on pioglitazone
Description: participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: add-on sulphonylurea
Description: participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
Study: NCT03151889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
Study: NCT02773329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensor-based interactive exercise (game-based exercise)
Description: This intervention includes interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks. Wearable sensors will provide real-time visual/auditory feedback from foot and ankle position and allowed perception of motor-errors during each motor-action.
Study: NCT02997241

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: OncoCare
Description: Personalized monitoring

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OncoCare
Description: Personalized monitoring

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: OncoCare
Description: Personalized monitoring

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OncoCare
Description: Personalized monitoring

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy for colorectal carcinoma
Description: chemotherapy for colorectal carcinoma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy for colorectal carcinoma
Description: chemotherapy for colorectal carcinoma
Study: NCT03565367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: gadolinium enhanced MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study: NCT02773329

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention without game-based exercise
Description: Subjects are asked to perform non-technology based foot and ankle exercises, which include body weight shifting and obstacle crossing tasks.
Study: NCT00976430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Bone marrow derived stem cells transplant
Description: Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
Study: NCT03088969

Intervention type: OTHER
Intervention: questionnaire RTWSE
Description: The evaluation of the self-efficiency perceived of return in the work of the patients by a validated auto-questionnaire is thus an additional objective parameter determining the risk factors of unfavorable evolution of the patients with Low Back Pain. This parameter also allows highlight other levers of actions in the therapeutic education.
Study: NCT04953871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF Inhibitor
Description: TNF inhibitors are widely used in patients with spondyloarthritis
Study: NCT00605267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg once daily oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrazole (Arimidex)
Description: 1 mg once daily oral dose
Study: NCT02585661

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy product fortified with enriched Fe-54 salt (1)
Description: 2.5mg of Fe per 100g of product

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy product fortified with enriched Fe-57 salt (2)
Description: 2.5mg of Fe per 100g of product
Study: NCT00605267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin acetate (Zoladex)
Description: 3.6mg/month depot injection
Study: NCT04240795

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low lubricity (LL) hydrogels containing fibre-based beads
Description: The preload is made from kappa-carrageenan and alginate beads of 450 μm size. It contains no additional macronutrient but has food-grade watermelon flavor, color, and non-nutritive sweetener.
Study: NCT01003002

Intervention type: DRUG
Intervention: Levodopa (delivered intravenously)
Description: One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
Study: NCT00605267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate (Zoladex)
Description: 3.6mg/month depot injection
Study: NCT03064880

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SV maximization
Description: Voluven solution 250 mL infusion per 5 minutes up to the platau of Flank-starling law: status to SV change \< 10% and maintained for 20 minutes
Study: NCT04056182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine 0.18 MG
Description: Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
Study: NCT00819507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinonide
Description: Fluocinonide 0.1% cream topical daily for two weeks
Study: NCT01805934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBLF
Description: The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RA
Description: The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).